Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum

Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum

<b>Background and Clinical Significance:</b> The mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approved treatment for first-line therapy i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacquelyn Shugarts, Aida Amado, Taylor Praska, Monica Camou, Jiaxin Niu
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Reports
Subjects:
METex14 subtype
leptomeningeal
duodenal metastases
Online Access:https://www.mdpi.com/2571-841X/8/2/96
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items